Estriol-Progesterone Therapy Eases Menopause Brain Fog
Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The positive results could boost interest in hormone-based therapies for menopause-related cognitive symptoms, potentially benefiting companies like CleopatraRX that hold related patents. However, the small, uncontrolled nature of the study limits immediate market impact, and FDA approval remains a key hurdle.
A small pilot study by UCLA Health, published in Scientific Reports on September 1, 2026, found that a combination hormone therapy of estriol and progesterone significantly improved self-reported cognitive symptoms ('brain fog') in 20 menopausal women after 12 months of treatment. Improvements were reported in concentration, working memory, processing speed, verbal memory, and problem-solving. Preclinical experiments in midlife female mice supported these findings, showing reduced hippocampal pathology and improved cognitive performance. The treatment, marketed as PearlPAK by CleopatraRX, is not yet FDA-approved and is currently available only as a compounded medication in the U.S. The study's senior author, Dr. Rhonda Voskuhl, is an inventor on UCLA patents related to the treatment and serves as a medical advisor to CleopatraRX. The authors caution that the results are preliminary and require confirmation in larger, placebo-controlled trials.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard